Pharmacology Optimization
Pharmacology Optimization - Related Videos
09:58
Pharmacological and Functional Genetic Assays to Manipulate Regeneration of the Planarian Dugesia japonica
0 Views •
Cited by 17 •
2011
An attractive model for studying stem cell differentiation within a live animal is the planarian flatworm. Regeneration is studied by simple amputation experiments that are easily performed in a basic laboratory and are amenable to pharmacological and genetic (in vivo RNAi) manipulation as detailed by protocols in this article.
11:27
The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System
0 Views •
Cited by 9 •
2012
The goal of this technique is to assess serotonin (5-HT) neurotransmitter function in the live and free-breathing animal with pharmacological magnetic resonance imaging (phMRI) and an intravenous challenge with a selective serotonin reuptake inhibitor (SSRI), fluoxetine.
08:49
Assessing Changes in Volatile General Anesthetic Sensitivity of Mice after Local or Systemic Pharmacological Intervention
0 Views •
Cited by 23 •
2013
Loss of the righting reflex has long served as a standard behavioral surrogate for unconsciousness, also called hypnosis, in laboratory animals. Alterations in volatile anesthetic sensitivity caused by pharmacological interventions can be detected with a carefully controlled high-throughput assessment system, which may be adapted for delivery of any inhaled therapeutic.
03:37
Optimal Foraging - Concepts
0 Views •
2019
Optimal Foraging Organisms must acquire and use resources in their environment to survive. While food is one of the primary resources organisms must search for, individuals also need to seek habitats, shelter, and mates. This process of searching for resources is known as foraging, which involves a series of costs and benefits. More specifically, acquiring a resource provides the organism with a benefit, however, searching and capturing the resource requires expenditure of time and energy.
12:37
Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
0 Views •
Cited by 13 •
2013
Epidermal melanin is induced by topical application of forskolin in a murine model of the fair-skinned UV-sensitive human. Pharmacologic manipulation of cAMP levels in the skin and epidermal darkening strongly protect against UV-mediated inflammation (sunburn) as measured by the minimum erythematous dose (MED) assay.
FAQs
Pharmacokinetics and pharmacodynamics must be interpreted together: pharmacokinetics links a regimen to drug exposure, while pharmacodynamics links exposure to the clinical response. Optimization therefore considers whether a concentration is likely to produce the intended effect, not merely whether a dose was administered. This relationship helps clinicians balance insufficient treatment against concentration-related adverse effects.
Disease state and organ function can change how a medication behaves in a patient. Impaired organ function may alter drug handling, while the disease itself can modify the relationship between exposure and response. Drug interactions add another source of variability. Considering these factors when refining treatment helps prevent a standard regimen from producing inadequate benefit or excessive toxicity.
Therapeutic drug monitoring adds measured drug concentrations to the optimization process when concentration information can inform treatment decisions. Clinicians can interpret those measurements alongside the patient’s response, organ function, disease state, and concurrent medications. The resulting assessment supports evidence-based dose or schedule adjustments rather than relying on the initial regimen throughout therapy.
A practical sequence is to evaluate the treatment goal and patient-specific factors, select an appropriate drug and regimen, observe therapeutic response and adverse effects, and reassess as treatment progresses. Pharmacokinetic and pharmacodynamic information, together with organ function, interactions, and monitoring results when available, guides subsequent refinement. This iterative approach keeps treatment aligned with changing clinical needs.
Individualized adjustment becomes especially relevant when disease state, organ function, drug interactions, or patient response makes the expected effect or toxicity difficult to predict. In these situations, clinicians can use ongoing assessment to decide whether the chosen medication, dose, or schedule remains appropriate. The aim is not maximal exposure, but the best balance between therapeutic benefit and adverse effects.
In clinical practice, optimization can be evaluated through the balance of therapeutic response, medication safety, and adverse effects over time. It also provides a framework for explaining why a regimen was changed as new response, interaction, or organ-function information becomes available. These outcomes support safer prescribing and evidence-based continuation or modification of therapy.